Get the Stockscreener App
6.87
0.73%
+0.05
After Hours:
6.61
-0.26
-3.78%
Nkarta Inc stock is currently priced at $6.87, with a 24-hour trading volume of 974.91K.
It has seen a +0.73% increased in the last 24 hours and a -30.40% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $6.76 pivot point. If it approaches the $7.06 resistance level, significant changes may occur.
Previous Close:
$6.82
Open:
$6.83
24h Volume:
974.91K
Market Cap:
$483.83M
Revenue:
-
Net Income/Loss:
$-117.50M
P/E Ratio:
-2.6836
EPS:
-2.56
Net Cash Flow:
$-114.31M
1W Performance:
-5.76%
1M Performance:
-30.40%
6M Performance:
+241.79%
1Y Performance:
+44.63%
1D Range:
$6.52
$7.14
52W Range:
$1.28
$16.24
Nkarta Inc Stock (NKTX) Company Profile
Name
Nkarta Inc
Sector
Industry
Phone
650-215-0385
Address
6000 Shoreline Court, Suite 102, South San Francisco
Nkarta Inc Stock (NKTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-10-22 | Initiated | Canaccord Genuity | Buy |
| Jul-28-22 | Initiated | Needham | Buy |
| Jul-18-22 | Initiated | SVB Leerink | Outperform |
| Mar-11-22 | Initiated | Raymond James | Outperform |
| Mar-08-22 | Initiated | H.C. Wainwright | Buy |
| Jan-06-22 | Initiated | William Blair | Outperform |
| Nov-18-21 | Initiated | SMBC Nikko | Outperform |
| Jul-16-21 | Initiated | Oppenheimer | Outperform |
| Aug-04-20 | Initiated | Cowen | Outperform |
| Aug-04-20 | Initiated | Evercore ISI | Outperform |
| Aug-04-20 | Initiated | Mizuho | Buy |
| Aug-04-20 | Initiated | Stifel | Buy |
View All
Nkarta Inc Stock (NKTX) Latest News
Small-Cap Firm Century Therapeutics' Expands into Autoimmune Diseases, Analyst Says Clade Therapeutics Acquisition Intriguing
Benzinga
Nkarta to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.
Nasdaq Turns Higher; Akanda Shares Plunge
Benzinga
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Benzinga
Crude Oil Moves Higher; US New Home Sales Fall In February
Benzinga
Nkarta Announces Pricing of $240 Million Underwritten Offering
GlobeNewswire Inc.
Nkarta Inc Stock (NKTX) Financials Data
Nkarta Inc (NKTX) Net Income 2024
NKTX net income (TTM) was -$117.50 million for the quarter ending December 31, 2023, a -3.22% decrease year-over-year.
Nkarta Inc (NKTX) Cash Flow 2024
NKTX recorded a free cash flow (TTM) of -$114.31 million for the quarter ending December 31, 2023, a -9.79% decrease year-over-year.
Nkarta Inc (NKTX) Earnings per Share 2024
NKTX earnings per share (TTM) was -$2.40 for the quarter ending December 31, 2023, a +9.43% growth year-over-year.
Nkarta Inc Stock (NKTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| George Simeon | Director |
Mar 27 '24 |
Buy |
10.00 |
2,000,000 |
20,000,000 |
1,548,341 |
| Brandenberger Ralph | Chief Technical Officer |
Mar 01 '24 |
Option Exercise |
3.89 |
6,763 |
26,308 |
88,339 |
| Brandenberger Ralph | Chief Technical Officer |
Mar 01 '24 |
Sale |
12.51 |
8,367 |
104,671 |
79,972 |
| Trager James | Chief Scientific Officer |
Feb 12 '24 |
Sale |
12.00 |
4,143 |
49,716 |
149,415 |
| HASTINGS PAUL J | Chief Executive Officer |
Jan 16 '24 |
Sale |
8.74 |
9,697 |
84,752 |
390,507 |
| Trager James | Chief Scientific Officer |
Jan 16 '24 |
Sale |
8.74 |
4,560 |
39,854 |
153,558 |
| Hager Alicia J. | Chief Legal Officer |
Jan 16 '24 |
Sale |
8.74 |
4,554 |
39,802 |
107,942 |
| Shook David | Chief Medical Officer |
Jan 16 '24 |
Sale |
8.74 |
3,552 |
31,044 |
114,980 |
| Brandenberger Ralph | Chief Technical Officer |
Jan 16 '24 |
Sale |
8.74 |
2,512 |
21,955 |
81,576 |
| Shook David | Chief Medical Officer |
Aug 21 '23 |
Sale |
1.83 |
1,331 |
2,436 |
60,532 |
About Nkarta Inc
Nkarta, Inc., a biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its co-lead product candidates are NKX101, a pre-clinical product that enhances the power of innate NK biology to detect and kill cancerous cells; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded in 2015 and is headquartered in South San Francisco, California.
1.53%
3.38%
Cap:
|
Volume (24h):